A Causal Association Between Atrial Fibrillation and Depression: Evidence From Mendelian Randomization Analyses.

Int J Psychiatry MedJan 20, 2026 (epub)
Clinical ResearchCardiologyPsychiatry

ZhiFei Sun, XiaoDing Wang, QingHe Zhao et al.

✦ AI-curated · Sources linked

In 30 seconds

This two-sample Mendelian randomization study examined whether atrial fibrillation (AF) is causally associated with depression, using genetic data from separate AF and depression genome-wide association studies and a meta-analysis of results from two depression datasets. Genetically predicted AF was associated with increased depression risk, with a combined odds ratio of 29.19 (95% CI = 4.43-192.13, P < 0.001). Results were consistent across sensitivity analyses, and MR-Egger analysis detected no evidence of gene pleiotropy. The findings support a causal association within the assumptions of the Mendelian randomization approach.

Key findings

  • Genetically predicted AF was associated with higher depression risk: combined odds ratio 29.19 (95% CI = 4.43-192.13, P < 0.001).
  • The association was identified using 15 single nucleotide polymorphisms as markers.
  • Alternative Mendelian randomization sensitivity analyses produced consistent results; MR-Egger detected no evidence of gene pleiotropy.

Why it matters

The findings suggest that AF may have implications beyond cardiovascular outcomes, with a potential causal link to depression. This supports attention to mental health in research on AF and highlights the value of considering psychological outcomes alongside cardiac disease. The estimate is based on genetic instruments and should be interpreted within the assumptions of Mendelian randomization.

What to keep in mind

The study relies on Mendelian randomization assumptions and genetic instruments; the abstract does not report clinical follow-up or direct assessment of depression after AF.

Source

Published in Int J Psychiatry Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.